PROM1 and hepatocellular carcinoma: <h4>Background</h4>This meta-analysis was conducted to investigate whether CD133 could be used as a biomarker to predict prognosis in hepatocellular carcinoma patients.<h4>Methods</h4>We systematically retrieved relevant studies from these databases as of February 2026.